RHC
FY11
NPAT $220.6m
EPS. $1.011
DPS. $0.52
FY15
NPAT. $412.1m
EPS. $1.966
DPS. $1.01
FY16 in Australia RHC completing build of an extra 534 beds and 19 theatres.
Continued double digit eps growth to me values RHC as strong growth stock with low risk.
Negatives:
Australia health funds controlling price
Medicare review
NHS tariff
French private hospital tariff
Positives:
Ageing and growing populations in their markets
Improved economy in UK
Procurement strength
Power with funders in Australia
Movement into Asia
Risk adverse management
IMHO, Stock will head to $100 over next two years.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$33.71 |
Change
-0.030(0.09%) |
Mkt cap ! $7.783B | |||
| Open | High | Low | Value | Volume |
| $33.75 | $33.86 | $33.68 | $2.219M | 65.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 211 | $33.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $33.72 | 627 | 13 |
View Market Depth
| Last trade - 11.55am 16/09/2025 (20 minute delay) ? |
| RHC (ASX) Chart |